Immix Biopharma (IMMX) Net Equity Issued and Repurchased (2022 - 2025)

Immix Biopharma (IMMX) has 4 years of Net Equity Issued and Repurchased data on file, last reported at $95.5 million in Q4 2025.

• For the quarter ending Q4 2025, Net Equity Issued and Repurchased changed N/A year-over-year to $95.5 million; the trailing twelve-month figure through Dec 2025 stood at $106.3 million (up 566.55% YoY), and the FY2025 full-year result was $107.4 million, up 573.47% from the prior year.
• Net Equity Issued and Repurchased grew to $95.5 million in Q4 2025, from $10.8 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $95.5 million in Q4 2025 to a low of -$2.4 million in Q4 2022.
• A 4-year average of $15.4 million and a median of $4.7 million in 2023 frame the typical range for Net Equity Issued and Repurchased.
• Across the five-year window, Net Equity Issued and Repurchased plunged 96.43% in 2023 and jumped 15245.16% in 2024, its largest moves.
• Tracing IMMX's Net Equity Issued and Repurchased over 4 years: stood at -$2.4 million in 2022, then soared by 123.95% to $584073.0 in 2023, then soared by 2630.15% to $15.9 million in 2024, then surged by 498.98% to $95.5 million in 2025.
• Business Quant data shows IMMX's Net Equity Issued and Repurchased at $95.5 million in Q4 2025, $10.8 million in Q3 2025, and $15.9 million in Q1 2024.